- Home
- BIIB vs PBA Comparison
BIIB vs PBA Comparison
Compare BIIB & PBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PBA
- Stock Information
- Founded
- BIIB 1978
- PBA 1997
- Country
- BIIB United States
- PBA Canada
- Employees
- BIIB N/A
- PBA N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PBA Oil & Gas Production
- Sector
- BIIB Health Care
- PBA Energy
- Exchange
- BIIB Nasdaq
- PBA Nasdaq
- Market Cap
- BIIB 18.8B
- PBA 21.8B
- IPO Year
- BIIB 1991
- PBA N/A
- Fundamental
- Price
- BIIB $125.00
- PBA $37.55
- Analyst Decision
- BIIB Buy
- PBA Buy
- Analyst Count
- BIIB 27
- PBA 1
- Target Price
- BIIB $188.17
- PBA $59.00
- AVG Volume (30 Days)
- BIIB 1.3M
- PBA 1.6M
- Earning Date
- BIIB 07-31-2025
- PBA 08-07-2025
- Dividend Yield
- BIIB N/A
- PBA 5.31%
- EPS Growth
- BIIB 26.39
- PBA N/A
- EPS
- BIIB 10.12
- PBA 2.13
- Revenue
- BIIB $9,816,400,000.00
- PBA $5,653,459,489.00
- Revenue This Year
- BIIB N/A
- PBA $13.50
- Revenue Next Year
- BIIB N/A
- PBA $0.62
- P/E Ratio
- BIIB $12.41
- PBA $17.61
- Revenue Growth
- BIIB 1.59
- PBA 29.95
- 52 Week Low
- BIIB $110.04
- PBA $34.13
- 52 Week High
- BIIB $238.00
- PBA $43.44
- Technical
- Relative Strength Index (RSI)
- BIIB 45.14
- PBA 47.35
- Support Level
- BIIB $123.21
- PBA $36.53
- Resistance Level
- BIIB $129.27
- PBA $38.07
- Average True Range (ATR)
- BIIB 3.00
- PBA 0.74
- MACD
- BIIB -0.77
- PBA -0.02
- Stochastic Oscillator
- BIIB 21.06
- PBA 29.64
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.